Highlights in this issue:

- **Predicting the Glomerular Filtration Rate in Bariatric Surgery Patients**
  Friedman, A.N.; Moe, S.; Fadel, W.F.; Inman, M.; Mattar, S.G.; Shihabi, Z.; Quinney, S.K.

- **Effect of Food Insecurity on Chronic Kidney Disease in Lower-Income Americans**

- **Elevated Osteoprotegerin Predicts Declining Renal Function in Elderly Women: A 10-Year Prospective Cohort Study**
Chronic kidney disease is a global major health issue that ultimately leads to end-stage renal disease, a devastating condition requiring costly renal replacement therapy. Given this background, extensive understanding of the pathogenesis of the disease and exploring novel therapeutic targets will help to alleviate disease progression, improve prognosis and reduce its impact on the global economic burden. Currently, primary glomerulonephritis is the leading cause of chronic kidney disease and end-stage renal disease in China and many other countries. Recently, there has been much progress with regard to pathogenesis as well as treatment of primary glomerulonephritis. Clinical data from Chinese studies have significantly contributed to the making of international guidelines and histological classifications of the disease. This book focuses on the cutting-edge knowledge and provides up-to-date information on primary glomerulonephritis. Topics covered are IgA nephropathy, focal segmental glomerulosclerosis, membranous nephropathy, membranoproliferative glomerulonephritis, and crescentic glomerulonephritis.

Contents

Preface: Chen, N.
Overview
• Primary Glomerulonephritis in Mainland China: An Overview: Xie, J.; Chen, N.
• Advances in the Pathology of Glomerular Diseases: Weening, J.J.; Ronco, P.; Remuzzi, G.
• Evaluation of Anemia and Serum iPTH, Calcium, and Phosphorus in Patients with Primary Glomerulonephritis: Li, Y.; Zhang, W.; Ren, H.; Wang, W.; Shi, H.; Li, X.; Chen, X.; Shen, P.; Wu, X.; Xie, J.; Chen, N.

IgA Nephropathy
• Role of Podocyte Injury in IgA Nephropathy: Menon, M.C.; Chuang, P.Y.; He, J.C.
• Genetic Studies of IgA Nephropathy: What Have We Learned from Genome-Wide Association Studies: Xie, J.; Shapiro, S.; Ghavri, A.
• Immunopathological Predictors of Prognosis in IgA Nephropathy: Tomino, Y.
• Treatment of Progressive IgA Nephropathy: An Update: Wang, W.; Chen, N.

Focal Segmental Glomerulosclerosis
• Different Targets for Treating Focal Segmental Glomerular Sclerosis: Coppo, R.
• Screening of ACTN4 and TRPC6 Mutations in a Chinese Cohort of Patients with Adult-Onset Familial Focal Segmental Glomerulosclerosis: Zhang, Q.; Ma, J.; Xie, J.; Wang, Z.; Zhu, B.; Hao, X.; Yang, L.; Ren, H.; Chen, N.
• Increased Risk of Treatment Failure and End-Stage Renal Disease in Familial Segmental Glomerular Sclerosis: Hao, X.; Xie, J.; Ma, J.; Wang, Z.; Zhou, Q.; Yang, L.; Pan, X.; Ren, H.; Chen, N.
• Treatment and Prognosis of Primary Focal Segmental Glomerulosclerosis: Ren, H.; Shen, P.; Li, X.; Pan, X.; Zhang, Q.; Feng, X.; Zhang, W.; Chen, N.
• New Insights into Treatment of Nephrotic Syndrome in Children: Wang, X.; Xu, H.

Membranous Nephropathy
• Pathogenesis of Membranous Nephropathy: A New Paradigm in Evolution: Glassock, R.J.
• Short-Term Complications of Membranous Nephropathy: Barbour, S.; Reich, H.; Cattran, D.
• Tacrolimus Combined with Corticosteroids in Idiopathic Membranous Nephropathy: A Randomized, Prospective, Controlled Trial: Xu, J.; Zhang, W.; Xu, Y.; Shen, P.; Ren, H.; Wang, W.; Li, X.; Pan, X.; Chen, N.

Membranoproliferative Glomerulonephritis
• Membranoproliferative Glomerulonephritis – Mechanisms and Treatment: Appel, G.B.
• Re-Evaluation of the Classification System for Membranoproliferative Glomerulonephritis: Lu, Y.; Shen, P.; Li, X.; Xu, Y.; Pan, X.; Wang, W.; Chen, X.; Zhang, W.; Ren, H.; Chen, N.
• C3 Glomerulopathy: Servais, A.; Noël, L.-H.; Frémeaux-Bacchi, V.; Lesavre, P.
• Hepatitis C Virus-Associated Glomerulonephritis: Tang, S.C.W.; Lai, K.N.

Crescentic Glomerulonephritis
• Pathogenesis of Rapidly Progressive Glomerulonephritis: What Do We Learn? Chen, Y.-X.; Chen, N.
• ANCA-Associated Renal Vasculitis – An Update: Tesar, V.; Hruskova, Z.
• Management of Crescentic Glomerulonephritis: What Are the Recent Advances? Li, X.; Chen, N.
• Plasma Exchange in the Treatment of Rapidly Progressive Glomerulonephritis: Chen, X.; Chen, N.

The easiest way to order: www.karger.com
Nephrology

Guidelines for Authors

Submission
The American Journal of Nephrology only accepts on-line submissions to:
http://mc.manuscriptcentral.com/ajn
All further technical instructions can be found there.

Conditions
The journal will not publish articles which have been previously reported at any length or articles being considered for publication elsewhere. The authors must include a statement to this effect in their cover letter. If publication of the data in any form has occurred or is being contemplated, a copy of such publications, tables and references will be included with the submitted manuscript. Failure to comply with this directive or discovery of any manuscript text, figure(s), or table(s) duplication will result in immediate retraction of the manuscript and/or article and the authors will not be allowed to submit any future manuscripts to this journal for a period of 3 years. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications. The manuscript should be written in English and the editors reserve the right to make appropriate corrections in grammar and style. Accepted papers become the permanent property of the American Journal of Nephrology and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. Information concerning financial disclosures (i.e., grants, funding, support, etc.) should be placed at the foot of the title page.

Types of Article for Acceptance
(1) Original Reports: Representing full sets of completed experiments in the areas of either clinical or basic research that answer a given question. Max. 5,000 words, incl. references and a maximum of 4 tables and/or figures.
   a) Transplantation: Manuscripts under this section include both basic and translational topics. Original experimental data are preferred; however, other content will be considered. Guidelines for this category are similar to the other original reports.
   b) Patient-oriented, translational research.
   c) Laboratory investigation.
(2) In-Depth Topic Reviews: Covering a timely topic by experts in the field. An Abstract is required and should be divided into Background, Summary, and Key Messages. Max. 6,000 words, incl. figures and references.
(3) Nephrology Grand Rounds: We welcome submissions to this section which is designed as a forum for nephrology trainees to discuss disease presentations or cases deserving exceptional merit. The section, however, is intended to extend far beyond the scope of a typical case report. Specifically, we seek case series (e.g. 5 or 6 cases) representing either similar illnesses or noteworthy unusual manifestations. It is expected that papers will incorporate not only a thorough but also a critical review of the literature. The intent is for senior co-authors and active involvement on their parts. Submissions are limited to 2,500 words, 1 figure, 1 table and 20 references.
(4) Hot Topics in Nephrology: A Debate (by invitation only): These will be debate forums of unsolved and important clinical issues in nephrology. There will be a pro and con position and each will consist of 1,500 words with a maximum of 7 key references. The topic will be determined by the editorial board but any proposals are welcomed.
(5) Invited Editorials: The Editor(s) will invite editorials on specifically selected articles. The editorial will have a maximum of 1,000 words and up to 10 references (one of which should be the paper being reviewed). Also, a maximum of one figure or table is allowed.
(6) Hypotheses:
   a) The paper should be unique and describe a substantial advance in concept development that is testable but has not yet been tested as it is rather difficult to carry-out. New data are not part of a hypothesis, but a section on how to test your idea must be included.
   b) You should express your line of reasoning in no more than 1,500 words, 10 references, and an abstract of approximately 250 words.

Conflicts of Interest
Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the article.

Ethics
Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute's committee on human research. Further, they should also state that animal experiments conform to institutional standards.

Plagiarism Policy
Plagiarism is misrepresenting somebody else's published intellectual work-product as your own (Note: this definition excludes 'self-plagiarism'). In short, it is a misuse of source material. Whether intentional or unintentional, plagiarism is a serious violation of the American Journal of Nephrology policy. Periodically, manuscripts are screened for plagiarism and if your manuscript is found to be consistent with what the Editors define* as plagiarism prior to review of the manuscript then:
1) it will be rejected without review and the author(s) notified as such with a chance for rebuttal.
If a manuscript is found to contain evidence of plagiarism after acceptance and/or publication then:
1) the author(s) will be notified, as in the previous situation, and offered a chance for rebuttal.
If the rebuttal arguments are not found to be satisfactory, as judged by the Editors, the manuscript will be rejected and the author sanctioned from publishing additional papers in the journal for a period to be determined by the Editorial Board. The period of sanction imposed is dependent on the magnitude of plagiarism with a minimum sanction of one year.

If a manuscript already published in the Journal is found to exhibit evidence of plagiarism as defined by the Editors*, then we will request a retraction. *Definition of plagiarism – a 25% similarity in the Results or Discussion that exactly reproduces another paper.

Arrangement
Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, a short title for use as running head, conflict of interest statement, key words, and word count. Manuscripts are to be double-spaced and formatted using the same font, size 12 throughout text and references.
Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.
Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstracts of Original Reports: Each paper needs an abstract of up to 250 words. It should be structured as follows: Background/Aims: What is the major problem that prompted the study? Methods: How was the study performed? Results: Most important findings? Conclusion: Most important conclusion?

Abstracts of In-Depth Topic Reviews: Should be divided into the following subsections: Background, Summary, and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review.

Footnotes: Avoid footnotes.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Average table = 250 words. The maximum size of all uploaded files is 40 Mb.

Color Illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.
Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.– per page.

References
In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publica-
tions which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples
(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2003;131:14–18.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in creating persistent identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in creating persistent identifiers for articles.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.–, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice™ service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy is available at http://publicaccess.nih.gov/FAQs.htm#a1.

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s Choice™ feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Page Charges
Original Reports exceeding the first 4 printed pages which are free will cost CHF 410.– per extra page.

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, as well as corrections after approval to publication, are charged to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

Transforming Vesalius
The medical revolution of the 16th century brought to life for the 21st century

ANNA VesALIUS
The Fabric of the Human Body
An Annotated Translation of the 1543 and 1555 Editions of “De Humani Corporis Fabrica” by DANIEL H. GARRISON, MALCOLM H. HAST

For the first time ever, both editions of Andreas Vesalius’s masterpiece “De Humani Corporis Fabrica” are accessible in the English language. They were critically compared and published in a modern layout transforming the Renaissance anatomical atlas for the 21st-century reader. More than 5,000 annotations cover anything from antique sources over Galenic references to the medical and cultural background of Vesalius’ time. To enable the reader and medical student to really study Vesalius’ woodcut illustrations, the images were digitally enhanced and often enlarged to feature his painstaking work of marking each pertinent anatomical part with characters. All over Vesalius’ descriptive text, the standard Latin Nomina Anatomica and Terminologia Anatomica provide the reader with the modern medical terminology.

For more information and easy ordering, please visit www.vesalius-fabrica.com
Contents

See the journal website for contents
15th Congress of the International Society of Peritoneal Dialysis

ISPD

7th – 10th September, 2014
Madrid, Spain

www.ispdmadrid2014.com

Important Deadlines

Abstract Submission
March 14th 2014

Early Bird Registration
July 15th 2014

PD: The Patient Comes First!
**APCN2014**

The 14th Asian Pacific Congress of Nephrology
Tokyo, Japan

**Date:** May 14 (Wed) - 17 (Sat), 2014

**Venue:** Shinagawa Prince Hotel

**Congress President:** Yasuhiko Tomino, MD, PhD

(Professor, Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan)

**URL:** http://www.mtoyou.jp/apcn2014/

**E-mail:** apcn2014@mtoyou.jp

<table>
<thead>
<tr>
<th>Registration fee</th>
<th>Early (by Feb 28, 2014)</th>
<th>Late (after Mar 1, 2014)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doctors / Others</td>
<td>JPY 35,000</td>
<td>JPY 45,000</td>
</tr>
<tr>
<td>Student / Fellow / Trainee / Nurse / Allied Health Care Staff</td>
<td>Free</td>
<td></td>
</tr>
<tr>
<td>Accompanying Person(s)</td>
<td>JPY 10,000</td>
<td>JPY 10,000</td>
</tr>
</tbody>
</table>

【Program main topics】

1. Diabetic kidney disease
2. IgA nephropathy
3. Nephrotic Syndrome and Podocyte Biology
4. Acute Kidney Injury
5. Hypertension
6. Renal replacement therapy
7. IgG4-related kidney disease
8. Renal regeneration

**Period of Abstract Submission**

September 10 (Tue) – December 10 (Tue), 2013

*Date and time should follow the Japanese Standard Time*

Further conference information should be checked on the website!

**URL:** http://www.mtoyou.jp/apcn2014/

**E-mail:** apcn2014@mtoyou.jp
The American Journal of Nephrology is a peer-reviewed journal that focuses on timely topics in both basic science and clinical research. Papers are divided into several sections, including:

- Original reports, spanning clinical, basic and outcomes research
- In-depth topic reviews on specific topics selected by the Editor and Associate Editors
- Invited debates — selected on ‘hot topics’ determined by the editorial board

Responding to the ever increasing pace in research, the American Journal of Nephrology adheres to a very tight publication schedule: accepted papers appear online within 5–6 weeks of acceptance.

Selected contributions

- Stem Cells and Their Role in Renal Ischaemia Reperfusion Injury: Bagul, A. (London); Frost, J.H. (Oxford); Drage, M. (London)
- Anti-Oxidative Effect of Vitamin D Analog on Incipient Vascular Lesion in Non-Obese Type 2 Diabetic Rats: Kono, K.; Fujii, H.; Nakai, K.; Goto, S. (Kobe); Kitazawa, R.; Kitazawa, S. (Kobe/Toon); Shinohara, M. (Tokyo); Hirata, M.; (Shizuoka); Fukagawa, M. (Kobe/Isehara); Nishi, S. (Kobe)
- Determinants of Cardiovascular Risk in Haemodialysis Patients: Post hoc Analyses of the AURORA Study: Schneider, A. (Glasgow/Würzburg); Jardine, A.G. (Glasgow); Schneider, M.P. (Glasgow/Erlangen); Holdaas, H.; Holme, I.; (Oslo); Fellstroem, B.C. (Uppsala); Zannad, F. (Nancy); Schmieder, R.E. (Erlangen) on behalf of the AURORA Study Group
- Pulmonary Hypertension in Renal Disease: Epidemiology, Potential Mechanisms and Implications: Kawar, B.; Ellam, T.; Jackson, C.; Kiely, D.G. (Sheffield)
- Vitamin D Treatment and Mortality in Chronic Kidney Disease: A Systematic Review and Meta-Analysis: Duranton, F. (Montpellier); Rodriguez-Ortiz, M.E. (Cordoba); Duny, Y. (Montpellier); Rodriguez, M. (Cordoba); Daurès, J.-P.; Argilés, A. (Montpellier)
- Metabolic Syndrome, Vitamin D Deficiency and Hypoadiponectinemia among Nondiabetic Patients Early after Kidney Transplantation: Kulshrestha, S.; Ojo, A.O.; Luan, F.L.; (Ann Arbor, Mich.)
- Determinants of Fibroblast Growth Factor-23 and Parathyroid Hormone Variability in Dialysis Patients: Jia, T.; Qureshi, A.R. (Stockholm); Brandenburg, V. (Aachen); Ketteler, M. (Coburg); Barany, P.; Heimburger, O. (Stockholm); Uhlin, F.; Magnusson, P.; Fernström, A. (Linköping); Lindholm, B.; Stenvinkel, P.; Larsson, T.E. (Stockholm)
1 Specific Management of Anemia and Hypertension in Renal Transplant Recipients: Influence of Renin-Angiotensin System Blockade
Salzberg, D.J.; Karadsheh, F.F.; Haririan, A.; Reddivari, V.; Weir, M.R. (Baltimore, Md.)

20 BK Virus Replication in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

59 Cystatin C Enhances Glomerular Filtration Rate Estimating Equations in Kidney Transplant Recipients
Kukla, A.; Issa, N.; Jackson, S.; Spong, R. (Minneapolis, Minn.); Foster, M.C. (Baltimore, Md.); Matas, A.J.; Mauer, M.S.; Eckfeldt, J.H.; Ibrahim, H.N. (Minneapolis, Minn.)

75 Effects of Mesenchymal Stem Cells Transplanted at Different Time Points in a Rat Remnant Kidney Model

8 Predicting the Glomerular Filtration Rate in Bariatric Surgery Patients
Friedman, A.N.; Moe, S.; Fadel, W.F. (Indianapolis, Ind.); Inman, M. (Carmel, Ind.); Mattar, S.G. (Indianapolis, Ind.); Shihabi, Z. (Winston-Salem, N.C.); Quinney, S.K. (Indianapolis, Ind.)

27 Effect of Food Insecurity on Chronic Kidney Disease in Lower-Income Americans

36 Proteomic Analysis of Whole Glomeruli in Patients with IgA Nephropathy Using Microsieving

50 Pre-End-Stage Renal Disease Care Not Associated with Dialysis Facility Neighborhood Poverty in the United States
Plantinga, L.C.; Kim, M.; Goetz, M.; Kleinbaum, D.G.; McClellan, W.; Patzer, R.E. (Atlanta, Ga.)

66 Elevated Osteoprotegerin Predicts Declining Renal Function in Elderly Women: A 10-Year Prospective Cohort Study
Lewis, J.R.; Lim, W.H.; Zhu, K. (Perth, W.A.); Wong, G. (Sydney, N.S.W.); Dhaliwal, S.S.; Lim, E.M. (Perth, W.A.); Ueland, T.; Bollerslev, J. (Oslo); Prince, R.L. (Perth, W.A.)

Nephrology Grand Rounds

16 Reninoma: The Importance of Renal Vein Renin Ratios for Lateralisation and Diagnosis
Wolley, M.; Gordon, R.D.; Stowasser, M. (Brisbane, Qld.)

Future Perspectives

46 Perspective on Combination RAS Blocking Therapy: Off-TARGET, Dis-CORD, MAP-to-Nowhere, Low ALTITUDE, and NEPHRON-D
Luft, F.C. (Nashville, Tenn.)